Skip to main content

Table 3 Multivariable analysis for the risk factors of EBV and CMV infections post-transplantation

From: Effect of sorafenib maintenance on Epstein-Barr virus and cytomegalovirus infections in patients with FLT3-ITD AML undergoing allogeneic hematopoietic stem cell transplantation: a secondary analysis of a randomized clinical trial

Parameters HR 95% CI P value
EBV-DNAemia
EBV serostatus: D- /R+ vs other 2.142 0.956–4.797 0.064
ATG use in the conditioning: ATG vs no ATG# 4.408 1.967–9.878 *<0.001
EBV-associated disease
ATG use in the conditioning: ATG vs no ATG# 3.235 1.078–9.711 *0.036
CMV-DNAemia
CR status at transplant: ≥ CR2 vs CR1 1.222 0.931–1.603 0.149
ATG use in the conditionin: ATG vs no ATG# 2.797 1.783–4.387 *<0.001
Sorafenib pre-transplant: use vs no use 1.340 0.910–1.974 0.138
aGVHD& 1.641 1.067–2.522 *0.024
CMV-associated disease
aGVHD& 3.179 1.175–8.601 *0.023
  1. Abbreviations: EBV Epstein-Barr virus, D donor, R recipient, ATG antithymocyte immunoglobulin, CMV cytomegalovirus, CR complete remission, CR2 second CR, CR1 first CR, aGVHD acute graft-versus-host disease, HR hazard ratio, CI confidence interval. *P<0.05; # All patients undergoing haploidentical donor (HID)/HLA-matched unrelated donor (MUD) transplants received ATG as GVHD prophylaxis, and none of those undergoing HLA-matched sibling donor (MSD) transplants received ATG as GVHD prophylaxis. Considering there was collinearity between transplant modality (HID/MUD vs MSD) and ATG use in the conditioning (ATG vs no ATG), we only included ATG use in the conditioning in the analysis of risk factors for EBV/CMV infections. &Time-dependent covariate